Regeneron Pharmaceuticals, Inc. (LON: 0R2M)
London
· Delayed Price · Currency is GBP · Price in USD718.00
+10.71 (1.51%)
Dec 23, 2024, 7:14 PM BST
Regeneron Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 29, 2024 | Dec '23 Dec 30, 2023 | Dec '22 Dec 30, 2022 | Dec '21 Dec 30, 2021 | Dec '20 Dec 30, 2020 | Dec '19 Dec 30, 2019 | 2018 - 2014 |
| Net Income | 4,655 | 3,954 | 4,338 | 8,075 | 3,513 | 2,116 | Upgrade
|
| Depreciation & Amortization | 469.5 | 421 | 341.4 | 286.2 | 235.9 | 210.3 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | 195 | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -389.3 | 266.4 | 36.8 | -387 | -221.8 | -131.5 | Upgrade
|
| Stock-Based Compensation | 918.8 | 885 | 725 | 601.7 | 432 | 464.3 | Upgrade
|
| Other Operating Activities | -812.8 | -837.9 | -378.4 | 421.6 | 162.4 | -28.4 | Upgrade
|
| Change in Accounts Receivable | -518.9 | -338.8 | 707.8 | -1,927 | -1,356 | -523.7 | Upgrade
|
| Change in Inventory | -549.3 | -271.7 | -696.5 | -494.3 | -529.4 | -335.5 | Upgrade
|
| Change in Accounts Payable | 370.8 | 598.6 | -138.4 | 866.1 | 118.9 | 599 | Upgrade
|
| Change in Unearned Revenue | 292 | 37.9 | 32.4 | -120.2 | 148.1 | 139.5 | Upgrade
|
| Change in Other Net Operating Assets | -187.9 | -120.1 | -148.6 | -240.7 | 114.9 | -79.8 | Upgrade
|
| Operating Cash Flow | 4,247 | 4,594 | 5,015 | 7,081 | 2,618 | 2,430 | Upgrade
|
| Operating Cash Flow Growth | -18.70% | -8.39% | -29.18% | 170.47% | 7.74% | 10.70% | Upgrade
|
| Capital Expenditures | -807.7 | -718.6 | -590.1 | -551.9 | -614.6 | -429.6 | Upgrade
|
| Cash Acquisitions | -8.8 | -54.9 | -230.3 | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -120.4 | -207.8 | -1,027 | - | - | - | Upgrade
|
| Investment in Securities | -1,968 | -2,204 | -1,937 | -4,833 | 544 | -1,598 | Upgrade
|
| Investing Cash Flow | -2,885 | -3,185 | -3,785 | -5,385 | -70.6 | -2,028 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | 1,500 | - | Upgrade
|
| Long-Term Debt Issued | - | - | - | - | 1,982 | - | Upgrade
|
| Total Debt Issued | - | - | - | - | 3,482 | - | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | -1,500 | - | Upgrade
|
| Total Debt Repaid | - | - | - | - | -1,500 | - | Upgrade
|
| Net Debt Issued (Repaid) | - | - | - | - | 1,982 | - | Upgrade
|
| Issuance of Common Stock | 1,675 | 1,146 | 1,520 | 1,672 | 2,575 | 211.8 | Upgrade
|
| Repurchase of Common Stock | -3,153 | -2,936 | -2,529 | -2,678 | -6,528 | -463.9 | Upgrade
|
| Other Financing Activities | -33.4 | - | - | - | - | - | Upgrade
|
| Financing Cash Flow | -1,511 | -1,790 | -1,009 | -1,006 | -1,971 | -252.1 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.2 | -0.4 | - | - | - | - | Upgrade
|
| Net Cash Flow | -148.4 | -381.6 | 221.3 | 690.8 | 577 | 150.1 | Upgrade
|
| Free Cash Flow | 3,440 | 3,875 | 4,425 | 6,529 | 2,004 | 2,000 | Upgrade
|
| Free Cash Flow Growth | -25.30% | -12.42% | -32.23% | 225.90% | 0.15% | 10.40% | Upgrade
|
| Free Cash Flow Margin | 24.84% | 29.54% | 36.35% | 40.63% | 23.58% | 30.51% | Upgrade
|
| Free Cash Flow Per Share | 29.88 | 34.08 | 38.99 | 58.19 | 17.41 | 17.46 | Upgrade
|
| Cash Interest Paid | 73.1 | 73.1 | 53.7 | 55.8 | 23.2 | 25 | Upgrade
|
| Cash Income Tax Paid | 870.3 | 870.3 | 1,502 | 1,218 | 188.1 | 342.3 | Upgrade
|
| Levered Free Cash Flow | 2,248 | 2,763 | 2,628 | 4,309 | 1,192 | 1,424 | Upgrade
|
| Unlevered Free Cash Flow | 2,287 | 2,808 | 2,665 | 4,345 | 1,227 | 1,443 | Upgrade
|
| Change in Net Working Capital | 753.5 | 217.1 | -94.5 | 1,613 | 1,117 | 183.3 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.